PS
FLNA

Principal Securities’s Filana Therapeutics FLNA Stock Holding History

Principal Securities’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25
Closed -$73 – 3118
2025
Q3 		$73 Hold
25
– – ﹤0.01% 3709
2025
Q2 		$45 Hold
25
– – ﹤0.01% 3662
2025
Q1 		$59 Hold
25
– – ﹤0.01% 3532
2024
Q4 		$59 Sell
25
-25
-50% -$439 ﹤0.01% 3527
2024
Q3 		$1.47K Hold
50
– – ﹤0.01% 3039
2024
Q2 		$618 Hold
50
– – ﹤0.01% 3163
2024
Q1 		$1.01K Hold
50
– – ﹤0.01% 3041
2023
Q4 		$1.13K Buy
+50
New +$1.06K ﹤0.01% 2929

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Principal Securities's FLNA Position: Q4 2025 in Review

Principal Securities sold out of Filana Therapeutics (FLNA) in Q4 2025, closing a stake of 25 shares — an estimated $73 sold.

Principal Securities first reported a position in FLNA in Q4 2023 and held it in 8 quarters. The position peaked at $1.47K in Q3 2024. 107 funds tracked by Wall St. Rank hold FLNA as of Q4 2025.

  • Principal Securities reported no remaining Filana Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 25 Filana Therapeutics shares in Q4 2025, an estimated $73.
  • Principal Securities first reported a position in Filana Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Filana Therapeutics position peaked at $1.47K in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.